4/23
01:33 pm
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.
Low
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.
4/22
04:34 pm
fate
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting [Yahoo! Finance]
Medium
Report
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting [Yahoo! Finance]
4/22
04:30 pm
fate
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Medium
Report
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
4/11
08:06 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
4/6
04:00 am
fate
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress [Yahoo! Finance]
Medium
Report
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress [Yahoo! Finance]
4/3
08:24 am
fate
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
Low
Report
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
4/3
08:00 am
fate
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
Low
Report
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
4/2
04:01 pm
fate
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
3/27
01:29 pm
fate
Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
Low
Report
Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
3/19
08:56 am
fate
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement [Yahoo! Finance]
Low
Report
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement [Yahoo! Finance]
3/19
08:44 am
fate
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
Low
Report
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
3/19
08:08 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Neutral
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
3/12
04:26 pm
fate
Boundless Bio Starts $100 Million U.S. IPO Plan [Seeking Alpha]
Low
Report
Boundless Bio Starts $100 Million U.S. IPO Plan [Seeking Alpha]
3/5
04:01 pm
fate
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
3/1
08:19 am
fate
Fate Therapeutics to Present at Upcoming March Investor Conferences [Yahoo! Finance]
Medium
Report
Fate Therapeutics to Present at Upcoming March Investor Conferences [Yahoo! Finance]
3/1
08:19 am
fate
Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/1
08:00 am
fate
Fate Therapeutics to Present at Upcoming March Investor Conferences
Medium
Report
Fate Therapeutics to Present at Upcoming March Investor Conferences
2/29
06:19 am
fate
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported And Analysts Have Been Lifting Their Price Targets [Yahoo! Finance]
Low
Report
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported And Analysts Have Been Lifting Their Price Targets [Yahoo! Finance]
2/27
11:22 am
fate
Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y [Yahoo! Finance]
Medium
Report
Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y [Yahoo! Finance]
2/27
11:15 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target raised by analysts at Morgan Stanley from $3.00 to $7.00. They now have an "equal weight" rating on the stock.
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target raised by analysts at Morgan Stanley from $3.00 to $7.00. They now have an "equal weight" rating on the stock.
2/27
10:17 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target raised by analysts at Barclays PLC from $6.00 to $10.00. They now have an "overweight" rating on the stock.
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target raised by analysts at Barclays PLC from $6.00 to $10.00. They now have an "overweight" rating on the stock.
2/27
10:17 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target raised by analysts at BMO Capital Markets from $6.00 to $7.00. They now have a "market perform" rating on the stock.
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target raised by analysts at BMO Capital Markets from $6.00 to $7.00. They now have a "market perform" rating on the stock.
2/27
09:00 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target raised by analysts at Wedbush from $3.00 to $7.00. They now have a "neutral" rating on the stock.
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target raised by analysts at Wedbush from $3.00 to $7.00. They now have a "neutral" rating on the stock.
2/27
08:08 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
2/26
04:55 pm
fate
Fate Therapeutics Inc (FATE) Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
High
Report
Fate Therapeutics Inc (FATE) Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]